Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 2,201–2,300 of 15,747
Current and prospective computational approaches and challenges for developing COVID-19 vaccines
Hwang, W., Lei, W., Katritsis, N. M., MacMahon, M., Chapman, K. L., & Han, N. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.004 · Cited by 52
Hobohm, L., Sagoschen, I., Barco, S., Schmidtmann, I., Espinola-Klein, C., Konstantinides, S., Münzel, T., & Keller, K. (2022) · Viruses · doi:10.3390/v14020275 · Cited by 42
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
Ponce‐de‐León, S., Torres, M., Soto-Ramírez, L. E., Calva, J. J., Santillán‐Doherty, P., Carranza-Salazar, D. E., Carreño, J. M., Carranza, C., Juárez, E., Carreto-Binaghi, L. E., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00662-6 · Cited by 75
Higdon, M. M., Wahl, B., Jones, C., Rosen, J., Truelove, S., Baidya, A., Nande, A., ShamaeiZadeh, P., Walter, K., Feikin, D., et al. (2021) · medRxiv · doi:10.1101/2021.09.17.21263549 · Cited by 122
What does 95% COVID-19 vaccine efficacy really mean?
Olliaro, P. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00075-x · Cited by 49
Carazo, S., Skowronski, D. M., Brisson, M., Sauvageau, C., Brousseau, N., Gilca, R., Ouakki, M., Barkati, S., Fafard, J., Talbot, D. C., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.36670 · Cited by 51
Zhou, R., Wang, P., Wong, Y.-C., Xu, H., Lau, S.-Y., Liu, L., Mok, B. W.-Y., Peng, Q., Liu, N., Woo, K. F., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103762 · Cited by 52
Henoch-Schönlein purpura presenting post COVID-19 vaccination
Hines, A., Murphy, N. J., Mullin, C. M., Barillas, J., & Barrientos, J. C. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.079 · Cited by 52
Talotta, R., & Robertson, E. S. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.05.001 · Cited by 52
“Although there were no safety issues that emerged in clinical trials compared to the placebo group [57,58], one case report did describe the development of deep vein thrombosis in a 66-year-old woman with no prior coagulation defects one day after receiving the second dose of the BNT162b2 vaccine [59].”
Jafari, A., Pouya, F. D., Niknam, Z., Abdollahpour‐Alitappeh, M., Rezaei–Tavirani, M., & Rasmi, Y. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07132-7 · Cited by 55
“A two-dose regimen of this vaccine conferred 95% protection against SARS-CoV-2 in 16 years of age or older recipients [40].”
BackgroundWang, Y., Wang, X., Luu, L. D. W., Chen, S., Fu, J. X., Wang, S., Huang, X., Wang, L., Zhou, X., Chen, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848961 · Cited by 58
“Previous analysis of COVID19 vaccines has mainly focused on evaluatingimmunogenicity, as well as characterizing immune cell types and/or cytokines (3, 4, 6).”
MethodLipid nanoparticle-mediated mRNA delivery to CD34+ cells in rhesus monkeys
Kim, H., Zenhausern, R., Gentry, K., Lian, L., Huayamares, S. G., Radmand, A., Loughrey, D., Podilapu, A. R., Hatit, M. Z. C., Ni, H., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02470-2 · Cited by 72
Lieber, C. M., Cox, R. M., Sourimant, J., Wolf, J. D., Juergens, K. B., Phung, Q., Saindane, M., Smith, M. K., Sticher, Z. M., Kalykhalov, A. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32045-1 · Cited by 53
Jörrißen, P., Schütz, P., Weiand, M., Vollenberg, R., Schrempf, I. M., Ochs, K., Frömmel, C., Tepasse, P., Schmidt, H., & Zibert, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679841 · Cited by 53
“by induction of neutralizing antibodies (15, 16).”
BackgroundInfluentialLumley, S. F., Rodger, G., Constantinides, B., Sanderson, N., Chau, K. K., Street, T. L., O’Donnell, D., Howarth, A., Hatch, S. B., Marsden, B. D., et al. (2021) · medRxiv · doi:10.1101/2021.03.09.21253218 · Cited by 48
An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology
Gresham, L. M., Marzario, B., Dutz, J. P., & Kirchhof, M. G. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.01.047 · Cited by 51
Bouton, T. C., Lodi, S., Turcinovic, J., Schaeffer, B., Weber, S. E., Quinn, E., Korn, C., Steiner, J., Schechter-Perkins, E. M., Duffy, E., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab465 · Cited by 49
Cantrelle, F., Boll, E., Brier, L., Moschidi, D., Belouzard, S., Landry, V., Leroux, F., Dewitte, F., Landrieu, I., Dubuisson, J., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202109965 · Cited by 50
Chen, G., Li, X., Sun, M., Zhou, Y., Yin, M., Zhao, B., & Li, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669010 · Cited by 49
“We confirmed the favorable safety profiles of mRNA vaccines observed in a series of clinical trials (4, 5, 12).”
BackgroundResultInfluentialChange in age distribution of COVID-19 deaths with the introduction of COVID-19 vaccination
Pastorino, R., Pezzullo, A. M., Villani, L., Causio, F. A., Axfors, C., Contopoulos‐Ioannidis, D. G., Boccia, S., & Ioannidis, J. P. A. (2021) · Environmental Research · doi:10.1016/j.envres.2021.112342 · Cited by 44
“Several COVID-19 vaccines have shown very high efficacy for symptomatic infection in clinical trials (Polack et al., 2020; Voysey et al., 2021; Baden et al., 2021) and have also demonstrated high effectiveness for preventing hospitalization and death in preliminary analyses after wide deployment in…”
Population-level implications of the Israeli booster campaign to curtail COVID-19 resurgence
Gavish, N., Yaari, R., Huppert, A., & Katriel, G. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9836 · Cited by 50
Nano-Microparticle Platforms in Developing Next-Generation Vaccines
Cappellano, G., Abreu, H., Casale, C., Dianzani, U., & Chiocchetti, A. (2021) · Vaccines · doi:10.3390/vaccines9060606 · Cited by 53
“The first two vaccines approved by the European Medicines Agency (EMA) were the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), two mRNA vaccines encapsulated in liposomes targeting the viral spike protein [131,133].”
BackgroundMethodInfluentialLittler, D. R., Liu, M., McAuley, J., Lowery, S. A., Illing, P. T., Gully, B. S., Purcell, A. W., Chandrashekaran, I. R., Perlman, S. M., Purcell, D. F. J., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101362 · Cited by 52
“(2021) 297(6) 101362 binding-site of Nsp9 is conserved among diverse coronaviruses, and accordingly we also observed reduced viral titers upon infection with MERS-CoV.”
InfluentialZothantluanga, J. H., Abdalla, M., Rudrapal, M., Tian, Q., Chetia, D., & Li, J. (2022) · Polycyclic aromatic compounds · doi:10.1080/10406638.2022.2046613 · Cited by 63
Tsilingiris, D., Vallianou, N. G., Karampela, Ι., Liu, J., & Dalamaga, Μ. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100159 · Cited by 51
“Both available mRNA-based vaccines have shown remarkable efficacy in early clinical trials with rates of prevention of COVID-19 symptomatic infection as high as 95% and 94.1% respectively [3,4].”
InfluentialMeir, J., Abid, M. A., & Abid, M. B. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.09.016 · Cited by 52
Ryan, F. J., Norton, T. S., McCafferty, C., Blake, S. J., Stevens, N. E., James, J., Eden, G. L., Tee, Y. C., Benson, S. C., Masavuli, M. G., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100971 · Cited by 63
Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
Bauernfeind, S., Salzberger, B., Hitzenbichler, F., Scigala, K., Einhauser, S., Wagner, R., Gessner, A., Koestler, J., & Peterhoff, D. (2021) · Vaccines · doi:10.3390/vaccines9101089 · Cited by 48
“Systemic reactogenicity was more common and severe after the second dose with events transient and resolving within a couple of days [2].”
BackgroundLaurini, E., Marson, D., Aulic, S., Fermeglia, A., & Pricl, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-99827-3 · Cited by 48
Heshin‐Bekenstein, M., Ziv, A., Toplak, N., Hagin, D., Kadishevich, D., Butbul, Y., Saiag, E., Kaufman, A., Shefer, G., Sharon, O., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac103 · Cited by 51
Yam‐Puc, J. C., Hosseini, Z., Horner, E. C., Gerber, P. P., Beristain‐Covarrubias, N., Hughes, R., Lulla, A., Rust, M., Boston, R. H., Ali, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38810-0 · Cited by 56
Herpes zoster after ChAdOx1 nCoV‐19 vaccine: a case series
Vastarella, M., Picone, V., Martora, F., & Fabbrocini, G. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17576 · Cited by 49
The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection
Moga, E., Lynton‐Pons, E., & Domingo, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904686 · Cited by 52
Miyashita, K., Hozumi, H., Furuhashi, K., Nakatani, E., Inoue, Y., Yasui, H., Karayama, M., Suzuki, Y., Fujisawa, T., Enomoto, N., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2155250 · Cited by 50
“ments for COVID-19 are being established and vaccination against the virus is becoming more widespread [3,4], the spread of COVID-19 has not been controlled.”
BackgroundOmo‐Lamai, S., Wang, Y., Patel, M. N., Essien, E., Shen, M., Majumdar, A., Espy, C. L., Wu, J., Channer, B., Tobin, M. P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.16.589801 · Cited by 48
“In addition to efficient delivery of RNA, the other reason for the widespread use of LNPs is their safety record, which is well illustrated by the COVID-19 vaccines 4,5 .”
Vaccine allergy: evidence to consider for COVID-19 vaccines
Nilsson, L. E., Csuth, Á., Storsæter, J., Garvey, L. H., & Jenmalm, M. C. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000762 · Cited by 51
Nucleic acid-based drugs for patients with solid tumours
Huayamares, S. G., Loughrey, D., Kim, H., Dahlman, J. E., & Sorscher, E. J. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00883-1 · Cited by 61
COVID-19 Vaccination and The Eye
Wang, M. T. M., Niederer, R. L., McGhee, C. N. J., & Danesh-Meyer, H. V. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.02.011 · Cited by 50
Xu, K., Dai, L., & Gao, G. F. (2021) · International Immunology · doi:10.1093/intimm/dxab061 · Cited by 51
Hu, Z., Tao, B., Li, Z., Song, Y., Yi, C., Li, J., Zhu, M., Yi, Y., Huang, P., & Wang, J. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.01.030 · Cited by 52
Kolb, T., Fischer, S., Müller, L., Lübke, N., Hillebrandt, J., Andrée, M., Schmitz, M., Schmidt, C., Kücükköylü, S., Koster, L., et al. (2021) · Kidney360 · doi:10.34067/kid.0003512021 · Cited by 52
Spinelli, F. R., Favalli, E. G., Garufi, C., Cornalba, M., Colafrancesco, S., Conti, F., & Caporali, R. F. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02674-w · Cited by 49
“Patients treated with immunosuppressant were excluded from phase III BNT162b2 vaccine RCT; the trial included 118 patients with RMDs, of whom 62 patients in the vaccine group, without any data on the ongoing treatment [2].”
MethodResultDanese, E., Montagnana, M., Salvagno, G. L., Gelati, M., Peserico, D., Pighi, L., NITTO, S. D., Henry, B. M., Porru, S., & Lippi, G. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0339 · Cited by 65
Israeli, M., Finkel, Y., Yahalom-Ronen, Y., Paran, N., Chitlaru, T., Israeli, O., Cohen-Gihon, I., Aftalion, M., Falach, R., Rotem, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29896-z · Cited by 48
Artificial intelligence in drug development: reshaping the therapeutic landscape
Niazi, S. K., & Mariam, Z. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986251321704 · Cited by 82
Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery
Huang, P., Deng, H., Wang, C., Zhou, Y., & Chen, X. S. (2023) · Advanced Materials · doi:10.1002/adma.202307822 · Cited by 56
Putative Role of Vitamin D for COVID-19 Vaccination
Chiu, S.-K., Tsai, K., Wu, C., Zheng, C., Yang, C., Hu, W., Hou, Y., Lu, K., & Chao, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168988 · Cited by 56
“Clinical trials were conducted in adults in the United States and Germany [87].”
BackgroundNext generation self-replicating RNA vectors for vaccines and immunotherapies
Aliahmad, P., Miyake-Stoner, S. J., Geall, A. J., & Wang, N. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00435-8 · Cited by 55
Review of Covid-19 vaccine clinical trials - A puzzle with missing pieces
Kwok, H. F. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59170 · Cited by 53
“In the BNT162b2 phase III study [24], the vaccine efficacy was consistent among different age subgroups.”
BackgroundInfluentialSARS-CoV-2 Variants Identification: Overview of Molecular Existing Methods
Berno, G., Fabeni, L., Matusali, G., Gruber, C. E. M., Rueca, M., Giombini, E., & Garbuglia, A. R. (2022) · Pathogens · doi:10.3390/pathogens11091058 · Cited by 55
Can SARS‐CoV‐2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review
Desai, H. D., Sharma, K. H., Shah, A., Patoliya, J., Patil, A. D., Hooshanginezhad, Z., Grabbe, S., & Goldust, M. (2021) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.14521 · Cited by 53
Gordon, C. J., Lee, H. W., Tchesnokov, E. P., Perry, J. K., Feng, J. Y., Bilello, J. P., Porter, D., & Götte, M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101529 · Cited by 49
“were developed in less than a year after the World Health Organization (WHO) declared a pandemic in March 2020(3-6).”
Follmann, D. A., Fintzi, J., Fay, M. P., Janes, H., Baden, L. R., Sahly, H. M. E., Fleming, T. R., Mehrotra, D. V., Carpp, L. N., Juraska, M., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m20-8149 · Cited by 53
Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination
Sokal, A., Bastard, P., Chappert, P., Spaeth, G. B., Fourati, S., Vandenberghe, A., Lagouge-Roussey, P., Meyts, I., Gervais, A., Bouvier‐Alias, M., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220258 · Cited by 50
mRNA therapy at the convergence of genetics and nanomedicine
Conde, J., Langer, R., & Rueff, J. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01347-w · Cited by 51
Kahn, R. J., Holmdahl, I. E., Reddy, S. C., Jernigan, J. A., Mina, M. J., & Slayton, R. B. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab517 · Cited by 51
Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
Rubbert‐Roth, A., Vuilleumier, N., Ludewig, B., Schmiedeberg, K., Haller, C., & von Kempis, J. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00186-7 · Cited by 46
Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines
Lim, C. M. L., Komarasamy, T. V., Adnan, N. A. A., Radhakrishnan, A. K., & Balasubramaniam, V. R. M. T. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13276 · Cited by 66
“…vaccines against SARS- CoV-2 in clinical settings have inspired further research and development of mRNA-based vaccines for various other pathogens [33, 34]. mRNA vaccines offer the potential for fast, scalable and efficient large-scale production, coupled with the precise design of antigens [35,…”
BackgroundMouliou, D. S., & Dardiotis, E. (2022) · Diagnostics · doi:10.3390/diagnostics12071555 · Cited by 55
“In an ongoing trial, 21% of the BNT162b2 vaccine recipients reported related adverse events, a rate that is significant more than the placebo group (5%) [17].”
BackgroundInfluentialYamamoto, S., Maeda, K., Matsuda, K., Tanaka, A., Horii, K., Okudera, K., Takeuchi, J. S., Mizoue, T., Konishi, M., Ozeki, M., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1048 · Cited by 56
“Clinical trials show that the mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in lowering the risk of coronavirus disease 2019 (COVID-19) [1, 2].”
mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection
Rauch, S., Gooch, K., Hall, Y., Salguero, F. J., Dennis, M. J., Gleeson, F. V., Harris, D., Ho, C., Humphries, H. E., Longet, S., et al. (2020) · doi:10.1101/2020.12.23.424138 · Cited by 48
Yamana, T. K., Galanti, M., Pei, S., Fusco, M. D., Angulo, F. J., Moran, M. M., Khan, F. L., Swerdlow, D. L., & Shaman, J. L. (2023) · PLoS ONE · doi:10.1371/journal.pone.0275699 · Cited by 51
“effectiveness against infection (7-9) – i.”
SARS-CoV-2 Vaccine–induced Thyroiditis: Safety of Revaccinations and Clinical Follow-up
Oğuz, S. H., Şendur, S. N., İremli, B. G., Gürlek, A., Erbas, T. A., & Ünlütürk, U. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac049 · Cited by 53
Bruxvoort, K. J., Sy, L. S., Qian, L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3916094 · Cited by 48
SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques
Garrido, C., Curtis, A. D., Dennis, M. L., Pathak, S., Gao, H., Montefiori, D. C., Tomai, M. A., Fox, C. B., Kozlowski, P. A., Scobey, T., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abj3684 · Cited by 47
Cordeiro, A. S., Patil‐Sen, Y., Shivkumar, M., Patel, R., Khedr, A., & Elsawy, M. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122091 · Cited by 59
“Although no MVA vaccines against COVID-19 have yet entered human trials, several studies have shown to induce strong and specific cellular responses against SARS-CoV-2 spike in mice [110–112].”
BackgroundInfluentialKim, Y., Landstrom, A. P., Shah, S. H., Wu, J. C., & Seidman, C. E. (2024) · Circulation · doi:10.1161/cir.0000000000001296 · Cited by 91
Woo, W., Kim, A. Y., Yon, D. K., Lee, S. W., Hwang, J., Jacob, L., Koyanagi, A., Kim, M. S., Moon, D. H., Jung, J. W., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27501 · Cited by 52
“05% was reported, and myocarditis was not reported.(3) However, there have been emerging concerns regarding myocarditis as rare complication of mRNA‐based COVID‐19 vaccines, especially in young adults and adolescent males.”
BackgroundOseran, A. S., Song, Y., Xu, J., Dahabreh, I. J., Wadhera, R. K., de Lemos, J. A., Das, S. R., Sun, T., Yeh, R. W., & Kazi, D. S. (2023) · BMJ · doi:10.1136/bmj-2023-076222 · Cited by 49
Tragni, V., Preziusi, F., Laera, L., Onofrio, A., Mercurio, I., Todisco, S., Volpicella, M., Grassi, A., & Pierri, C. L. (2022) · The EPMA Journal · doi:10.1007/s13167-021-00267-w · Cited by 52
“…of vaccination by using new vaccines based on a cocktail of the newly identified (or predicted as dangerous) spike sequences (in the form of mRNA [19, 20] or proteins/subdomains [53–55]) showing high affinities for the human host-cell receptors and/or to design new targeted antibodies [7, 56]…”
MethodSARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses
Carnell, G., Ciazynska, K. A., Wells, D. A., Xiong, X., Aguinam, E. T., McLaughlin, S. H., Mallery, D. L., Ebrahimi, S., Ceron‐Gutierrez, L., Asbach, B., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00203-21 · Cited by 48
“The first three licensed vaccines require delivery of either mRNA (Pfizer/BioNTech [10] and”
Backgroundvan Doremalen, N., Schulz, J. E., Adney, D. R., Saturday, T. A., Fischer, R. J., Yinda, C. K., Thakur, N., Newman, J., Ulaszewska, M., Belij‐Rammerstorfer, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32248-6 · Cited by 42
Upadhyay, V., Lucas, A., Panja, S., Miyauchi, R., & Mallela, K. M. G. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101208 · Cited by 44
Toward Gene Transfer Nanoparticles as Therapeutics
Kavanagh, E. W., & Green, J. J. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102145 · Cited by 48
Optimal allocation of limited vaccine to control an infectious disease: Simple analytical conditions
Rao, I. J., & Brandeau, M. L. (2021) · Mathematical Biosciences · doi:10.1016/j.mbs.2021.108621 · Cited by 49
The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics
Muslimov, A. R., Tereshchenko, V., Shevyrev, D., Rogova, A. S., Lepik, K. V., Reshetnikov, V. V., & Ivanov, R. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914820 · Cited by 56
Pityriasis rosea‐like eruptions following vaccination with BNT162b2 mRNA COVID‐19 Vaccine
Cyrenne, B. M., Al‐Mohammedi, F., DeKoven, J. G., & Alhusayen, R. O. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17342 · Cited by 48
Diallo, B., Chasaide, C. N., Wong, T. Y., Schmitt, P., Lee, K. S., Weaver, K. L., Miller, O. A., Cooper, M., Jazayeri, S. D., Damron, F. H., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00665-3 · Cited by 51
COVID-19 mRNA Vaccination–Induced Lymphadenopathy Mimics Lymphoma Progression on FDG PET/CT
Xu, G., & Lü, Y. (2021) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003597 · Cited by 47
Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization
Ebenig, A., Muraleedharan, S., Kazmierski, J., Tödt, D., Auste, A., Anzaghe, M., Gömer, A., Postmus, D., Gogesch, P., Niles, M. A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111214 · Cited by 55
“Nevertheless, this potential risk was perceived also for vaccine-induced immune responses that target the closely related SARS-CoV-2 and triggered vaccine developers to aim for TH1-biased immunity and to assess the potential of immunopathogenesis in the available animal models (Anderson et al., 2020; Corbett et al., 2…”
COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series
Ruan, Z., Tang, Y., Li, C., Sun, C., Zhu, Y., Li, Z., & Chang, T. (2021) · Vaccines · doi:10.3390/vaccines9101112 · Cited by 49
Pulvirenti, F., Salinas, A. F., Milito, C., Terreri, S., Mortari, E. P., Quintarelli, C., Cecca, S. D., Lagnese, G., Punziano, A., Guercio, M., et al. (2021) · Cells · doi:10.3390/cells10112915 · Cited by 53
“Clinical trials showed an effectiveness of almost 95% in preventing severe COVID-19 disease [17].”
BackgroundStouten, V., Hubin, P., Haarhuis, F., van Loenhout, J. A. F., Billuart, M., Brondeel, R., Braeye, T., Oyen, H. J. V., Wyndham-Thomas, C., & Catteau, L. (2022) · Viruses · doi:10.3390/v14040802 · Cited by 53
Long, S. W., Olsen, R. J., Christensen, P. A., Subedi, S., Olson, R., Davis, J. J., Saavedra, M. O., Yerramilli, P., Pruitt, L., Reppond, K., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.03.004 · Cited by 47
Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment
Grinshpun, A., Rottenberg, Y., Ben‐Dov, I. Z., Oiknine‐Djian, E., Wolf, D. G., & Kadouri, L. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100283 · Cited by 45
“Yet, IgG antibody levels have been shown to serve as a good correlative to neutralization.(7,20,23) As for immunotherapy using checkpoint inhibitors, the possible heightened immunogenicity of the COVID-19 vaccine, as reflected by the higher OR for antibody levels of”
Disparities in COVID-19 vaccine uptake among health care workers
Farah, W. H., Breeher, L. E., Shah, V. P., Hainy, C. M., Tommaso, C. P., & Swift, M. D. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.045 · Cited by 52
“Over the last two years, several public health interventions were placed to address this burden, including the rapid development of several COVID-19 vaccines [1,3,4].”
BackgroundmRNA delivery in cancer immunotherapy
Zhong, Y., Du, S., & Dong, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.03.001 · Cited by 55
Tinnitus following COVID-19 vaccination: report of three cases
Parrino, D., Frosolini, A., Gallo, C., et al. (2021) · International Journal of Audiology · doi:10.1080/14992027.2021.1931969 · Cited by 47
Drug-Induced Liver Injury After COVID-19 Vaccine
Mann, R., Sekhon, S., & Sekhon, S. S. (2021) · Cureus · doi:10.7759/cureus.16491 · Cited by 47
“It is unclear if that was a likely risk factor for hepatotoxicity in this case [5].”
BackgroundAdvances in the design and delivery of RNA vaccines for infectious diseases
Lokras, A. G., Bobak, T. R., Baghel, S. S., Sebastiani, F., & Foged, C. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115419 · Cited by 56
COVID-19 and the Endocrine System: A Review of the Current Information and Misinformation
Mirza, S. A., Sheikh, A. A. E., Barbera, M., Ijaz, Z., Javaid, M. A., Shekhar, R., Pal, S., & Sheikh, A. B. (2022) · Infectious Disease Reports · doi:10.3390/idr14020023 · Cited by 56
“Furthermore, SARS-CoV-2 has also been found in the semen of men with acute infection as well as in recovering patients [48].”
BackgroundB Cell Depletion and SARS‐CoV ‐2 Vaccine Responses in Neuroimmunologic Patients
Kornek, B., Leutmezer, F., Rommer, P. S., Koblischke, M., Schneider, L., Haslacher, H., Thalhammer, R., Zimprich, F., Zulehner, G., Bsteh, G., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26309 · Cited by 53
Ruddy, J. A., Boyarsky, B. J., Werbel, W. A., Bailey, J. R., Karaba, A. H., Garonzik‐Wang, J., Segev, D. L., & Durand, C. M. (2021) · AIDS · doi:10.1097/qad.0000000000002945 · Cited by 49
Gagné, M., Moliva, J. I., Foulds, K., Andrew, S., Flynn, B., Werner, A. P., Wagner, D. A., Teng, I.-T., Lin, B. C., Moore, C., et al. (2022) · bioRxiv · doi:10.1101/2022.02.03.479037 · Cited by 77
(2021) · doi:10.1101/2021.03.03.21252872 · Cited by 655
Parents’ hesitation about getting their children vaccinated against COVID-19 in Japan
Yoda, T., & Katsuyama, H. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1981087 · Cited by 56
“Recent data suggest the incidence of anaphylaxis episodes attributable to the Pfizer/BioNTech vaccine in roughly 1:200,000 individuals.(15,18) This is in sharp contrast to the rate of less than 1 per million doses for most vaccines.”
ResultMoon, A. M., Webb, G. J., García‐Juárez, I., Kulkarni, A. V., Adalı, G., Wong, D., Lusina, B., Dalekos, G. Ν., Masson, S., Shore, B. M., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1853 · Cited by 48
Immunity to SARS-CoV-2: Lessons Learned
FERGIE, J. E., & Srivastava, A. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654165 · Cited by 50
From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines
Lopez-Cantu, D. O., Wang, X., Carrasco-Magallanes, H., Afewerki, S., Zhang, X., Bonventre, J. V., & Ruiz‐Esparza, G. U. (2022) · Nano-Micro Letters · doi:10.1007/s40820-021-00771-8 · Cited by 53
SARS-CoV-2 variant trends in Ireland: Wastewater-based epidemiology and clinical surveillance
Reynolds, L. J., González, G., Sala‐Comorera, L., Martin, N. A., Byrne, A., Fennema, S., Holohan, N., Kuntamukkula, S. R., Sarwar, N., Nolan, T. M., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.155828 · Cited by 46
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.